Special Feature

User Panel

My Panel

My Panel

Bookmark Science Articles

Recent News
Bookmark / Share This Science Site

Immunotherapy of spontaneous mammary carcinoma with fusions of dendritic cells and mucin 1-positive carcinoma cells.

Immunotherapy of spontaneous mammary carcinoma with fusions of dendritic cells and mucin 1-positive carcinoma cells. Research Abstract Details 

Research Abstract Table of Contents

Jump to the:

  • Abstract Text of This Paper
  • Journal Published
  • MeSH Keywords of This Abstract
  • Chemicals and Substances Used in this Paper
  • Grants and Granting Agency of this Research
  • Database Accession Numbers Used in this Paper
  • Related Papers
  • Related Research Tags
  • Rate this Research Paper
  • Immunotherapy of spontaneous mammary carcinoma with fusions of dendritic cells and mucin 1-positive carcinoma cells. Abstract Text:

    dongshu chenDongshu Chen,jianchuan xiaJianchuan Xia,yasuhiro tanakaYasuhiro Tanaka,hongsong chenHongsong Chen,shigeo koidoShigeo Koido,oliver wernetOliver Wernet,pinku mukherjeePinku Mukherjee,sandra j gendlerSandra J Gendler,donald kufeDonald Kufe,jianlin gongJianlin Gong,

    The tumour-associated antigen mucin 1 (MUC1) is a multifunctional protein involved in protection of mucous membranes, signal transduction, and modulation of the immune system. More than 70% of cancers overexpress MUC1, making MUC1 a potential target for immunotherapy. In the present study, MUC1 transgenic mice were crossed with syngeneic strains that express the polyomavirus middle-T oncogene (PyMT) driven by the mouse mammary tumour virus promoter long-terminal repeat (MMTV-LTR). The resultant breed (MMT mice) developed spontaneous MUC1-expressing mammary carcinomas with 100% penetrance at 8-15 weeks of age. As found in human breast cancer, the mammary carcinoma in MMT mice arose in multiple stages. Immunization with fusions of dendritic cells and MUC1-positive tumour cells (FC/MUC1) induced MUC1-specific immune responses that blocked or delayed the development of spontaneous breast carcinomas. In contrast, there was no delay of tumour development in MMT mice immunized with irradiated MC38/MUC1 tumour cells. The efficacy of fusion cells was closely correlated with the timing of initial immunization. Immunization with FC/MUC1 initiated in MMT mice at < 1, 1-2 and 2-3 months of age rendered 33, 5 and 0% of mice free of tumour, respectively, up to 6 months. Whereas mice immunized in the later stage of tumour development succumbed to their disease, immunization resulted in control of tumour progression and prolongation of life. These results indicate that immunization with FC/MUC1 can generate an anti-MUC1 response that is sufficient to delay the development of spontaneous mammary carcinomas and control tumour progression in MMT mice.

    Immunotherapy of spontaneous mammary carcinoma with fusions of dendritic cells and mucin 1-positive carcinoma cells. Publishing Authors By Initials

    d chenD Chen,j xiaJ Xia,y tanakaY Tanaka,h chenH Chen,s koidoS Koido,o wernetO Wernet,p mukherjeeP Mukherjee,sj gendlerSJ Gendler,d kufeD Kufe,j gongJ Gong,

    For similar peptides: peptide fragments research abstracts see: peptides: peptide fragments research

    PUBMED ID PMID:

    MEDLINE DATE:

    Immunotherapy of spontaneous mammary carcinoma with fusions of dendritic cells and mucin 1-positive carcinoma cells. Journal Published:

    PUBLICATION TYPE: Research Support, U.S. Gov't,

    Journal: Immunology

    VOLUME: 109

    Page Numbers: 300-7

    Journal Abbreviation: Immunology

    ISSN: 0019-2805

    DAY: 1

    MONTH: Jun

    YEAR: 2003

    Immunotherapy of spontaneous mammary carcinoma with fusions of dendritic cells and mucin 1-positive carcinoma cells. Information

    Number of References:

    LANGUAGE: eng

    NlmUniqueID: 374672

    Immunotherapy of spontaneous mammary carcinoma with fusions of dendritic cells and mucin 1-positive carcinoma cells. Keywords Mesh Terms:

    KEYWORDS: Peptide Fragments

    MESH TERMS: metabolism

    Chemical & Substance for Abstract: Immunotherapy of spontaneous mammary carcinoma with fusions of dendritic cells and mucin 1-positive carcinoma cells. Information

    Substance Name: Peptide Fragments

    Registry Number: 0

    Grant and Affiliation Information for Immunotherapy of spontaneous mammary carcinoma with fusions of dendritic cells and mucin 1-positive carcinoma cells.

    AFFILIATION: Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA.

    Country: England

    England Research PublicationEngland Research Publication

    AGENCY: United States NCI

    GRANT: R01 CA87057

    ACRONYM: CA

    MEDLINETA: Immunology

    REFSOURCE:

    DATABASENAME:

    ACCESSION NUMBER:

    Number Hits: 0

    Immunotherapy of spontaneous mammary carcinoma with fusions of dendritic cells and mucin 1-positive carcinoma cells Related Publications

     

    Molecular Station USER Menu

    Welcome to Molecular Station!

    You have to register before you can post on our forums or use our advanced features. Register Now! Its Free and Fast!

    Already registered? Login now below.

    User Name:

    Password:

    Already registered and Forgot your password? Click below to recover it.

    Recover Lost Password

    Join now - it's fast and free!

    Molecular Station is THE largest network of researchers, scientists and science lovers anywhere!

    Research Terms of Usage and Disclaimer
    Home
    Features

    Protocols

    DNA Forum

    Science Forum

    DNA Forum
    Biology Forum

    Science News


    [CaRP] XML error: Invalid document end at line 2

    For more click here:Science News